











### OS non-squamous




### PFS PD-L1 nonselective



### PFS PD-L1 1%-50%





Figure\_1\_Supp Forest plots of heterogeneity analysis. Atez, Atezolizumab; Camre, Camrelizumab; Chemo, Chemotherapy; Durva, Durvalumab; Nivo, Nivolumab; Pembro, Pembrolizumab; Treme, Tremelimumab; Ipi, Ipilimumab